Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Invivyd Inc Market Cap
The Invivyd Inc (IVVD) share price is expected to increase by 652.17% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered IVVD. Price targets range from $1.1 at the low end to $15 at the high end. The current analyst consensus for IVVD is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Invivyd Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Invivyd Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of IVVD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Patrick Trucchio HC Wainwright & Co. | Buy | $15 | Reiterates | Aug 27, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $15 | Reiterates | May 24, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $15 | Reiterates | May 14, 2024 |
| Evan Wang Guggenheim | Buy | $9 | Upgrade | Apr 5, 2024 |
| Maxwell Skor Morgan Stanley | Overweight | $10 | Upgrade | Mar 26, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $15 | Reiterates | Mar 25, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $15 | Maintains | Jan 18, 2024 |
| Jeffrey Hung Morgan Stanley | Equal-Weight | $4 | Upgrade | Dec 19, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $5 | Reiterates | Aug 14, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $5 | Reiterates | Jul 18, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $5 | Reiterates | Jun 23, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $5 | Reiterates | May 15, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $5 | Initiates | May 1, 2023 |
| Matthew Harrison Morgan Stanley | Underweight | $1 | Maintains | Mar 27, 2023 |
| Matthew Harrison Morgan Stanley | Underweight | $2 | Maintains | Jan 24, 2023 |
Morgan Stanley | Underweight | Maintains | Sep 16, 2022 | |
| Matthew Harrison Morgan Stanley | Underweight | $3 | Maintains | Sep 14, 2022 |
Morgan Stanley | Underweight | Maintains | May 17, 2022 | |
Morgan Stanley | Underweight | Downgrade | Jan 6, 2022 | |
Jefferies | Hold | Downgrade | Dec 22, 2021 |
When did it IPO
2021
Staff Count
94
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Heidi Spurling M.S.
Market Cap
$106.9M
In 2023, IVVD generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IVVD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sun, 12 Nov 2023
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Invivyd, Inc. (NASDAQ:IVVD ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Corporate Participants Scott Young - SVP, Investor Relations and Corporate Communications Dave Hering - Chief Executive Officer Pete Schmidt - Chief Medical Officer Jeremy Gowler - Chief Operating and Commercial Officer Bill Duke - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Jenna Li - Jefferies Maxwell Skor - Morgan Stanley Evan Wang - Guggenheim Securities Operator Welcome to the Invivyd Third Quarter 2023 Financial Results and Recent Business Highlights Call.
Thu, 09 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- u00a0Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the quarter ended September 30, 2023, and recent business highlights.
Thu, 02 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 9, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023, and recent business highlights.
Tue, 31 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Mon, 11 Sep 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Initial primary endpoint data anticipated in late 2023 or early Q1 2024 Initial primary endpoint data anticipated in late 2023 or early Q1 2024
Wed, 06 Sep 2023
Sentiment - NEGATIVE
Source - InvestorPlace
Summary - Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
